Jesus Duran, MD
Geriatric Medicine · Las Cruces, NMNPI 1972714806
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.7% of the total across 72 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 20 manufacturers reported payments, led by AstraZeneca at 30.6% of the total. 2025 is the largest year on record at $661, more than ten times the $13 reported in 2020.
Across 72 payments — averaging $21.68 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$477
- GSK$241
- Harmony Biosciences LLC$140
- Novo Nordisk$108
- Eisai Inc.$79
- Lilly USA, LLC$69
- plus $446 from 14 others
What the payments were for
- Food & beverage$1,556100%
- Education$50%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 20 | $477 |
| GSK | 12 | $241 |
| Harmony Biosciences LLC | 4 | $140 |
| Novo Nordisk | 7 | $108 |
| Eisai Inc. | 4 | $79 |
| Lilly USA, LLC | 4 | $69 |
| Mylan Specialty L.p. | 2 | $64 |
| Abiomed | 3 | $64 |
| Bayer | 3 | $55 |
| Verona Pharma, Inc. | 2 | $50 |
| Boehringer Ingelheim | 2 | $44 |
| Viatris Specialty LLC | 1 | $33 |
| AbbVie | 1 | $28 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Sanofi-aventis U.S. LLC | 1 | $17 |
| Amgen | 1 | $16 |
| Pfizer | 1 | $16 |
| Exact Sciences | 1 | $15 |
| Idorsia Pharmaceuticals US Inc | 1 | $14 |
| Insulet Corporation | 1 | $13 |
How this compares
Too few geriatric medicine providers in New Mexicoto place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 137 | $137,598 |
| OzempicSemaglutide | 87 | $136,951 |
| JardianceEmpagliflozin | 73 | $102,501 |
| TrulicityDulaglutide | 63 | $86,688 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 65 | $69,108 |
| JanuviaSitagliptin Phosphate | 50 | $65,071 |
| XareltoRivaroxaban | 48 | $56,205 |
| RybelsusSemaglutide | 20 | $42,373 |
| MounjaroTirzepatide | 20 | $42,024 |
| FarxigaDapagliflozin Propanediol | 23 | $29,728 |
| MyrbetriqMirabegron | 18 | $18,436 |
| Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $13,563 |
| Levothyroxine Sodium | 905 | $11,722 |
| Atorvastatin Calcium | 764 | $9,999 |
| Breo ElliptaFluticasone/Vilanterol | 19 | $9,560 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $108 | $179,324107 claims |
| PfizerEliquis | $16 | $137,598137 claims |
| Lilly USA, LLCTrulicity, Mounjaro | $69 | $128,71383 claims |
| Boehringer IngelheimJardiance | $44 | $102,50173 claims |
| GSKTrelegy Ellipta, Breo Ellipta | $241 | $78,66884 claims |
| AstraZenecaFarxiga, Symbicort, Bevespi Aerosphere | $477 | $38,37346 claims |
| AbbVieSynthroid | $28 | $5,09185 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few geriatric medicine providers in New Mexicoon file to place this against a meaningful peer group, so we don't.
Other geriatric medicine in Las Cruces
- Anastasiia NeelagaruAlbuquerque$5K
- Janice KnoefelAlbuquerque$4K
- Kirsten SilveyAlbuquerque$256
- Christine LopezRaton$201
- Eric MetzlerSocorro$120
- Nadia MarshAlbuquerque$119
- M LodhiAlbuquerque$107
- Toni PriceCuba$91
- Lenard WagnerLovington$62
- Brian MathwichSanta Fe$61
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.